financial results

The company posted Q4 revenues of $15.9 million, up from $10.9 million in Q4 2018, and beat the consensus Wall Street estimate of $14.2 million.

The firm said it saw "significant deterioration" in February due to "ongoing and protracted" disruptions resulting from the novel coronavirus and an extended Lunar New Year holiday.

The company said clinical services revenues and diagnostic testing volumes rose during the quarter, but that PAMA continued to negatively affect reimbursements.

The Belgian diagnostics company said it has partnered with Bristol-Myers Squibb to register its MSI test as a companion diagnostic in China. 

More than 70 percent of ePlex analyzer placements in the fourth quarter were within labs that previously had a competitive analyzer, the firm said.

Of the 28 companies in the index, nine companies' share prices increased while the share values of 19 declined month over month.  

The company said it continues to see the global tuberculosis market expanding, and it is investing in both commercial resources and R&D.

The company trimmed its net loss fell by three-fourths to $11.8 million in the quarter as it continues to rein in costs.